Abstract: The present invention provides novel complexes consisting of certain GLP-1 molecules associated with a divalent metal cation that is capable of co-precipitating with a GLP-1 molecule. Pharmaceutical compositions and methods of using such complexes for enhancing the expression of insulin in B-type islet cells is claimed, as is a method for treating maturity onset diabetes mellitus in mammals, particularly humans.
Abstract: A method of treatment of acne rosacea consists of the application, in the form of either a lotion or a cream, constituting a mixture of a therapeutically effective amount of invermectin in water, in the case of the lotion, and invermectin and a pharmaceutically acceptable carrier, in the case of the cream. Application to the affected area occurs daily for a period of one week and, thereafter, two to four times per month for a period of up to one year.
Abstract: Compounds are described which act as calcitonin mimetics. These compounds are useful in the treatment of diseases which are associated with bone resorption. Included among the calcitonin mimetics of the present invention are substituted piperazines. The calcitonin mimetics of the present invention are also useful in libraries and in assays for the determination of calcitonin receptor activity.
Type:
Grant
Filed:
February 23, 1998
Date of Patent:
September 26, 2000
Assignee:
ZymoGenetics, Inc.
Inventors:
Nand Baindur, Virender Labroo, Steven Stroop, Stephanie Beigel, Theresa Martinez, Charles R. Petrie, Mark W. Orme, Patricia A. McKernan, Emma E. Moore
Abstract: The invention refers to the use of a sulpholipid SQDG having formula (I), wherein R.sub.1 and R.sub.2, which are the same or different, are hydrogen or saturated or unsaturated, optionally hydroxy-substituted acyl groups, protonated or as a salt, for the preparation of a pharmaceutical composition for the treatment of inflammatory skin diseases or disorders, especially psoriasis. A pharmaceutical composition comprising an SQDG compound in combination with a polyunsaturated fatty acid and a therapeutically acceptable carrier is also described.
Type:
Grant
Filed:
April 27, 1999
Date of Patent:
September 26, 2000
Assignee:
Scotia Lipid Teknik AB
Inventors:
Mervi Vasange, Wenche Rolfsen, Lars Bohlin
Abstract: The present invention provides a method and composition for treating pruritus, and also psoriasis which includes applying a compound of formula (I) in a suitable formulation to the affected area. Compounds of formula (I) can also be formulated as a vaginal cream to inhibit viruses such as HIV, and possibly prevent the transmission of other sexually transmitted diseases.
Abstract: A composition is formed of chlorine dioxide and a phosphate added to a mixture of glucono delta lactone, glycerin and hydroxyethyl cellulose to form a lubricant that will stop itching by killing Candida species and several other organisms known to colonize the vagina.
Abstract: Methods are provided for measuring the accumulation of advanced glycosylation endproducts (AGEs), and for lowering the accumulation of advanced glycosylation endproducts, which are predicated on the discovery that such AGEs and their precedent glycotoxins are present in tobacco and its byproducts. More particularly, the methods focus on the observation that individuals who smoke or otherwise use tobacco have increased levels of AGEs relative to non-smoking individuals. The present methods relate to the measurement of AGE levels in both individuals and in tobacco and its byproduct, smoke, and to the treatment of such individuals with agents capable of reacting with glycosylation products to either avert or diminish the accretion of AGEs in the body.
Type:
Grant
Filed:
November 10, 1998
Date of Patent:
August 29, 2000
Assignee:
The Picower Institute for Medical Research
Inventors:
Richard J. Bucala, Helen Vlassara, Anthony Cerami, Carla J. Cerami, Henry W. Founds
Abstract: The present invention is directed to a method for the treatment of mammalian retrovirus infections, such as HIV, using combinations of retroviral protease inhibitors which are effective in preventing the replication of the retroviruses in vitro or in vivo. This invention, in particular, relates to protease inhibitor compounds used in combination therapy with other protease inhibitor compounds. This invention also relates to combination therapy with a combination of protease inhibitors and antiviral agents other than protease inhibitors.
Type:
Grant
Filed:
June 2, 1995
Date of Patent:
August 8, 2000
Assignee:
G.D. Searle & Co.
Inventors:
Simon P Tucker, Martin L Bryant, Karen E Potts, Mary L Smidt
Abstract: The present invention relates to compositions and methods for the treatment of oxidative epithelial damage, for inadequate surfactant production in lung disorders, and for disorders of the urinary bladder epithelium. The compositions of the present invention comprise dehydroepiandrosterone and vitamin A derivatives.
Abstract: The present invention is concerned with the use of a chemically-stabilized chlorite matrix for the parenteral treatment of HIV infections. The chlorite matrix is an isotonic solution containing 5 to 100 mMol ClO.sub.2- per liter of solution.
Abstract: The present invention provides a method of killing a cell by first administering to the cell a vitamin D derivative and subsequently administering to the cell a cytotoxic agent. Where the cell is within a tumor, the present invention provides a method of retarding the growth of the tumor by first administering the vitamin D derivative to the tumor and subsequently administering to the tumor the cytotoxic agent.
Type:
Grant
Filed:
August 29, 1997
Date of Patent:
July 11, 2000
Assignee:
University of Pittsburgh of the Commonwealth System of Higher Education
Abstract: Therapeutic compositions of microspheres for application to wounds and/or lesions for accelerating wound healing and muscle regeneration. The microspheres are made up of non-biodegradable material having a substantial surface charge. The therapeutic composition further includes a pharmaceutically acceptable carrier in which the microspheres are insoluble and a container for holding the composition. The therapeutic composition further contains pharmacologic agents or biologics that accelerate the wound healing process.
Abstract: A method of preventing and treating a viral condition caused by an enveloped virus is described, comprising using a therapeutically effective amount of a compound selected from the group consisting of a substituted hydroquinone and the corresponding benzoquinone, wherein said hydroquinone comprises a 2-R.sup.1, 3-R.sup.2 -1,4-hydroquinone where at least one of R.sup.1 and R.sup.2 include a carbon linkage to the benzene ring of the hydroquinone. Particularly useful compounds include 5,8-dihydro-5,8-methano-1,4-naphthalenediol, 1,4-naphthoquinone, 3', 6'-dihydroxybenzo-norbornane, tert-butylhydroquinone, other diols, e.g. 1,5-naphthalenediol, and alkylated diols, e.g. 4-methoxy-1-naphthol.
Type:
Grant
Filed:
July 24, 1992
Date of Patent:
June 27, 2000
Assignees:
Seres Laboratories, Inc., University of California
Inventors:
Dale L. Bodian, Judith M. White, Irwin D. Kuntz, Jay F. Stearns, R. Bryan Yamasaki
Abstract: A topical mycological treatment composition for medical, veterinarian, or dental use contains as active ingredients clotrimazole, ketoconazole, micanazole, nystatin, tolnaftate, propionic acid, sodium propionate, undecelynic acid, and zinc undecelynate. These ingredients are contained in a natural cream base, and the base may also contain an anti-inflammatory agent and an antibacterial agent.
Abstract: Ophthalmic compositions and a method are disclosed for treating glaucoma and/or ocular hypertension in the mammalian eye by topically administering to the mammalian eye the ophthalmic composition of the invention which contains as the active ingredient one or more gamma aminobutyric acid agonist compounds.
Abstract: Derivatives of Phenyl Cycloamino Pyrimidinone are useful for the treatment of patients having precancerous lesions. These compounds are also useful to inhibit growth of neoplastic cells.
Abstract: This invention provides an improved etherification process that reduces the amount of acidic-ion-exchange-resin catalyst that is deactivated by nitriles. This process uses a water phase to remove nitriles from a hydrocarbon phase followed by an alcohol phase to remove the nitriles from the water phase. An hydrogenation catalyst is used to convert the nitriles to amines so that they can be more easily removed from the alcohol phase.
Type:
Grant
Filed:
May 30, 1996
Date of Patent:
March 14, 2000
Assignee:
Phillips Petroleum Company
Inventors:
Gary R. Patton, Robert O. Dunn, Gary A. Delzer, Marvin M. Johnson
Abstract: Synthetic lipid composition in which the content and the distribution of the fatty acids are similar to those of human milk fat, containing less than 2% by weight of free fatty acids, in which palmitic acid is predominantly at the 2-position of the triacylglycerols and the arachidonic and docosahexaenoic acids are distributed between the 1-, 2- and 3-positions and in particular predominantly at the 2-position of the triacylglycerols.
Type:
Grant
Filed:
July 13, 1998
Date of Patent:
March 7, 2000
Assignee:
Nestec S.A.
Inventors:
Junkuan Wang, Raymond Bertholet, Pierre Ducret, Mathilde Fleith
Abstract: Anti-pruritic pharmaceutical formulations containing kappa agonist compounds and methods of prevention or treatment of pruritus in a mammal with the anti-pruritic formulations.
Type:
Grant
Filed:
November 2, 1998
Date of Patent:
December 21, 1999
Assignee:
Adolor Corporation
Inventors:
John J. Farrar, An-Chih Chang, Virendra Kumar, Wei Yuan Zhang, Alan Cowan
Abstract: A pharmaceutical preparation comprising a stable, surface-active emulsion or dispersion of a pharmaceutical agent incorporated into an emulsion (i) having a hydrophobic discontinuous phase of a long chain carboxylic acid or ester or alcohol thereof dispersed in an aqueous phase or (ii) having a hydrophilic discontinuous phase dispersed in a hydrophobic phase of a long chain carboxylic acid or alcohol thereof. The emulsion with pharmaceutical agent is incorporated into a pharmaceutical carrier suitable for oral delivery.
Type:
Grant
Filed:
August 28, 1995
Date of Patent:
September 14, 1999
Assignee:
Shire Laboratories Inc.
Inventors:
Edward Rudnic, John McCarty, Beth Burnside, Charlotte McGuinness, George Belenduik